Marco had an exceptional academic career. He won the best PhD of the year award in Chemistry in his home country Germany and then went on to do a Post-Doc at the University of Cambridge.
During his time at Cambridge, Marco received a Marie-Curie fellowship, as well as a stipend from the Gates Foundation to do his own research. Marco worked with excellent people like Chris Abell (who would later become vice chancellor) and Tom Blundell, on the fragment based drug discovery company Astex that was acquired for $866 Million by Otsuka.
His work with Chris and Tom opened his eyes to the possibilities of launching his own company, as well as to the limitation of traditional approaches to drug development: The inability to predict clinical efficacy. Solving this problem became the mission of biotx.ai.
Marco is also on the scientific advisory board of the CRO Simbec-Orion.
His book, Chemical Biology and Drug Discovery, has sold over 50,000 copies.
LinkedIn: https://www.linkedin.com/in/marco-schmidt-7527aa19
Marco had an exceptional academic career. He won the best PhD of the year award in Chemistry in his home country Germany and then went on to do a Post-Doc at the University of Cambridge.
During his time at Cambridge, Marco received a Marie-Curie fellowship, as well as a stipend from the Gates Foundation to do his own research. Marco worked with excellent people like Chris Abell (who would later become vice chancellor) and Tom Blundell, on the fragment based drug discovery company Astex that was acquired for $866 Million by Otsuka.
His work with Chris and Tom opened his eyes to the possibilities of launching his own company, as well as to the limitation of traditional approaches to drug development: The inability to predict clinical efficacy. Solving this problem became the mission of biotx.ai.
Marco is also on the scientific advisory board of the CRO Simbec-Orion.
His book, Chemical Biology and Drug Discovery, has sold over 50,000 copies.
LinkedIn: https://www.linkedin.com/in/marco-schmidt-7527aa19